RVPHReviva Pharmaceuticals Holdings, Inc.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) has one year to prove it can survive the next catalyst — and the next — without collapsing into the next chapter of its long-running saga. The next big test is the post-data equity financing / capital raise on 2026-10-20, which could either be a lifeline or a last gasp. The modeled bull path is $0.54, the bear is $0.46, and the lean is bear — but the market is already betting on the next step being a bear. The company’s survival hinges on whether it can raise capital, report better-than-expected results, and avoid the Nasdaq’s minimum bid price rule. If it fails on any of those, it’s not just a stock losing value — it’s a company losing its listing.
The schedule
- Tue20Oct
- Sat14Nov
- Mon30Nov
- Sun14Feb
- Wed12May
- Sat14Aug
Past
- Wed12Aug
Actual outcome: Bear
Reviva Pharmaceuticals reported earnings in line with expectations, with an EPS of -0.19 versus the estimate of -0.19. The company filed a U.S. composition of matter patent application seeking accelerated review for a new form of brilaroxazine, which extends patent life and commercial exclusivity through 2046. These developments signaled potential long-term value and innovation, driving the stock higher despite the earnings miss.
- Mon30Mar
The release of top-line Phase 3 schizophrenia data for RVPH's lead candidate is a pivotal moment for the company. This data is essential for regulatory approval and could significantly influence investor sentiment and stock performance.
